Document is current

Any future updates will be listed below

OL3, a novel low-absorbed TGR5 agonist with reduced side effects, lowered blood glucose via dual actions on TGR5 activation and DPP-4 inhibition

Crossref DOI link: https://doi.org/10.1038/aps.2016.27

Published Online: 2016-06-06

Published Print: 2016-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark